R
RVPHW
OtherReviva Pharmaceuticals Holdings Inc - Warrants (14/12/2025)
—PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving RVPHW Today?
No stock-specific AI insight has been generated for RVPHW yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
RVPHW News
20 articles- Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric IndicationsYahoo Finance·Apr 23, 2026
- Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress PlansYahoo Finance·Apr 21, 2026
- RVPH: Shareholder Letter Introduces New IPYahoo Finance·Apr 20, 2026
- Reviva Announces Letter to ShareholdersYahoo Finance·Apr 15, 2026
- Does Cobenfy Have the Potential to Become a Top Drug for BMY?Yahoo Finance·Apr 9, 2026
- RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2Yahoo Finance·Apr 1, 2026
- Reviva Reports Full Year 2025 Financial Results and Recent Business HighlightsYahoo Finance·Mar 30, 2026
- Analysts Remain Confident in Reviva Pharmaceuticals Holdings (RVPH) Amid 1-for-20 Reverse Stock SplitYahoo Finance·Mar 25, 2026
- Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public OfferingYahoo Finance·Mar 23, 2026
- Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public OfferingYahoo Finance·Mar 19, 2026
- Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public OfferingYahoo Finance·Mar 18, 2026
- Reviva Reports Third Quarter 2025 Financial Results and Recent Business HighlightsYahoo Finance·Nov 13, 2025
- Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025Yahoo Finance·Nov 12, 2025
- Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary FibrosisYahoo Finance·Nov 10, 2025
- Reviva to Participate in the Spartan Capital Securities Second Annual Investor ConferenceYahoo Finance·Oct 29, 2025
- Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025Yahoo Finance·Oct 28, 2025
- Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global PartnersYahoo Finance·Oct 7, 2025
- Reviva to Participate in the 4th Annual Roth Healthcare Opportunities ConferenceYahoo Finance·Oct 2, 2025
- Reviva to Participate in the Lytham Partners Fall 2025 Investor ConferenceYahoo Finance·Sep 23, 2025
- Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public OfferingYahoo Finance·Sep 19, 2025
All 20 articles loaded
Price Data
Open—
Previous Close—
Day High—
Day Low—
52 Week High—
52 Week Low—
Fundamentals
Market Cap—
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding—
About Reviva Pharmaceuticals Holdings Inc - Warrants (14/12/2025)
Reviva Pharmaceuticals Holdings Inc - Warrants (14/12/2025) (RVPHW) · Other
Listed October 18, 2018
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SIC—
CIK—
Composite FIGI—
Share Class FIGI—